Serum IGFBP-2 and Risk of Atypical Hyperplasia of the Breast

Chelsea Catsburg, Marc J. Gunter, Lesley Tinker, Rowan T. Chlebowski, Michael Pollak, Howard Strickler, Michele L. Cote, David L. Page, Thomas E. Rohan

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Atypical hyperplasia of the breast (AH) is associated with increased risk of subsequent invasive breast cancer, yet little is known about the etiology of AH. Insulin-like growth factor binding protein 2 (IGFBP-2) may contribute to the development of AH due to its proliferative effects on mammary tissue. We conducted a nested case-control study of postmenopausal women enrolled in Women's Health Initiative-Clinical Trial. Cases were 275 women who developed incident AH during follow-up, individually (1: 1) matched to controls. Levels of IGFBP-2 were determined from fasting serum collected at baseline. Multivariable conditional logistic regression models were used to estimate odds ratios for the association of IGFBP-2 with risk of AH. Serum IGFBP-2 was associated with a nonsignificant decrease in risk for AH, when comparing the highest quartile to lowest quartile (OR = 0.65; 95% CI = 0.32-1.31). This decrease in risk was most evident when analyses were restricted to nondiabetic, nonusers of hormone therapy (OR = 0.33, 95% CI = 0.13-0.86, p<inf>trend</inf> = 0.06) and nondiabetic women who were overweight or obese (OR = 0.43, 95% CI = 0.18-1.03, p<inf>trend</inf> = 0.05). Results from this study provide some support for an inverse association between serum IGFBP2 levels and risk of AH, particularly in nondiabetic women who are overweight or obese. Further studies are required to confirm these results.

Original languageEnglish (US)
Article number203284
JournalJournal of Cancer Epidemiology
Volume2015
DOIs
StatePublished - 2015

Fingerprint

Insulin-Like Growth Factor Binding Protein 2
Hyperplasia
Breast
Serum
Logistic Models
Women's Health
Case-Control Studies
Fasting
Odds Ratio
Clinical Trials
Hormones
Breast Neoplasms

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Genetics
  • Epidemiology

Cite this

Serum IGFBP-2 and Risk of Atypical Hyperplasia of the Breast. / Catsburg, Chelsea; Gunter, Marc J.; Tinker, Lesley; Chlebowski, Rowan T.; Pollak, Michael; Strickler, Howard; Cote, Michele L.; Page, David L.; Rohan, Thomas E.

In: Journal of Cancer Epidemiology, Vol. 2015, 203284, 2015.

Research output: Contribution to journalArticle

Catsburg, C, Gunter, MJ, Tinker, L, Chlebowski, RT, Pollak, M, Strickler, H, Cote, ML, Page, DL & Rohan, TE 2015, 'Serum IGFBP-2 and Risk of Atypical Hyperplasia of the Breast', Journal of Cancer Epidemiology, vol. 2015, 203284. https://doi.org/10.1155/2015/203284
Catsburg, Chelsea ; Gunter, Marc J. ; Tinker, Lesley ; Chlebowski, Rowan T. ; Pollak, Michael ; Strickler, Howard ; Cote, Michele L. ; Page, David L. ; Rohan, Thomas E. / Serum IGFBP-2 and Risk of Atypical Hyperplasia of the Breast. In: Journal of Cancer Epidemiology. 2015 ; Vol. 2015.
@article{6dfe79aab29f4e20a024bd93503941bc,
title = "Serum IGFBP-2 and Risk of Atypical Hyperplasia of the Breast",
abstract = "Atypical hyperplasia of the breast (AH) is associated with increased risk of subsequent invasive breast cancer, yet little is known about the etiology of AH. Insulin-like growth factor binding protein 2 (IGFBP-2) may contribute to the development of AH due to its proliferative effects on mammary tissue. We conducted a nested case-control study of postmenopausal women enrolled in Women's Health Initiative-Clinical Trial. Cases were 275 women who developed incident AH during follow-up, individually (1: 1) matched to controls. Levels of IGFBP-2 were determined from fasting serum collected at baseline. Multivariable conditional logistic regression models were used to estimate odds ratios for the association of IGFBP-2 with risk of AH. Serum IGFBP-2 was associated with a nonsignificant decrease in risk for AH, when comparing the highest quartile to lowest quartile (OR = 0.65; 95{\%} CI = 0.32-1.31). This decrease in risk was most evident when analyses were restricted to nondiabetic, nonusers of hormone therapy (OR = 0.33, 95{\%} CI = 0.13-0.86, ptrend = 0.06) and nondiabetic women who were overweight or obese (OR = 0.43, 95{\%} CI = 0.18-1.03, ptrend = 0.05). Results from this study provide some support for an inverse association between serum IGFBP2 levels and risk of AH, particularly in nondiabetic women who are overweight or obese. Further studies are required to confirm these results.",
author = "Chelsea Catsburg and Gunter, {Marc J.} and Lesley Tinker and Chlebowski, {Rowan T.} and Michael Pollak and Howard Strickler and Cote, {Michele L.} and Page, {David L.} and Rohan, {Thomas E.}",
year = "2015",
doi = "10.1155/2015/203284",
language = "English (US)",
volume = "2015",
journal = "Journal of Cancer Epidemiology",
issn = "1687-8558",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Serum IGFBP-2 and Risk of Atypical Hyperplasia of the Breast

AU - Catsburg, Chelsea

AU - Gunter, Marc J.

AU - Tinker, Lesley

AU - Chlebowski, Rowan T.

AU - Pollak, Michael

AU - Strickler, Howard

AU - Cote, Michele L.

AU - Page, David L.

AU - Rohan, Thomas E.

PY - 2015

Y1 - 2015

N2 - Atypical hyperplasia of the breast (AH) is associated with increased risk of subsequent invasive breast cancer, yet little is known about the etiology of AH. Insulin-like growth factor binding protein 2 (IGFBP-2) may contribute to the development of AH due to its proliferative effects on mammary tissue. We conducted a nested case-control study of postmenopausal women enrolled in Women's Health Initiative-Clinical Trial. Cases were 275 women who developed incident AH during follow-up, individually (1: 1) matched to controls. Levels of IGFBP-2 were determined from fasting serum collected at baseline. Multivariable conditional logistic regression models were used to estimate odds ratios for the association of IGFBP-2 with risk of AH. Serum IGFBP-2 was associated with a nonsignificant decrease in risk for AH, when comparing the highest quartile to lowest quartile (OR = 0.65; 95% CI = 0.32-1.31). This decrease in risk was most evident when analyses were restricted to nondiabetic, nonusers of hormone therapy (OR = 0.33, 95% CI = 0.13-0.86, ptrend = 0.06) and nondiabetic women who were overweight or obese (OR = 0.43, 95% CI = 0.18-1.03, ptrend = 0.05). Results from this study provide some support for an inverse association between serum IGFBP2 levels and risk of AH, particularly in nondiabetic women who are overweight or obese. Further studies are required to confirm these results.

AB - Atypical hyperplasia of the breast (AH) is associated with increased risk of subsequent invasive breast cancer, yet little is known about the etiology of AH. Insulin-like growth factor binding protein 2 (IGFBP-2) may contribute to the development of AH due to its proliferative effects on mammary tissue. We conducted a nested case-control study of postmenopausal women enrolled in Women's Health Initiative-Clinical Trial. Cases were 275 women who developed incident AH during follow-up, individually (1: 1) matched to controls. Levels of IGFBP-2 were determined from fasting serum collected at baseline. Multivariable conditional logistic regression models were used to estimate odds ratios for the association of IGFBP-2 with risk of AH. Serum IGFBP-2 was associated with a nonsignificant decrease in risk for AH, when comparing the highest quartile to lowest quartile (OR = 0.65; 95% CI = 0.32-1.31). This decrease in risk was most evident when analyses were restricted to nondiabetic, nonusers of hormone therapy (OR = 0.33, 95% CI = 0.13-0.86, ptrend = 0.06) and nondiabetic women who were overweight or obese (OR = 0.43, 95% CI = 0.18-1.03, ptrend = 0.05). Results from this study provide some support for an inverse association between serum IGFBP2 levels and risk of AH, particularly in nondiabetic women who are overweight or obese. Further studies are required to confirm these results.

UR - http://www.scopus.com/inward/record.url?scp=84935916173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84935916173&partnerID=8YFLogxK

U2 - 10.1155/2015/203284

DO - 10.1155/2015/203284

M3 - Article

AN - SCOPUS:84935916173

VL - 2015

JO - Journal of Cancer Epidemiology

JF - Journal of Cancer Epidemiology

SN - 1687-8558

M1 - 203284

ER -